Shivani Modi MD

Most cancers aren’t hard to treat. They’re hard to detect early. Our new paper proposes an AI-enabled multi-omic stool screening paradigm for colorectal cancer, integrating: 🧬 tumor DNA 🦠 microbiome 🧫 RNA 🧪 proteomic & metabolomic signals AI can fuse these signals into precision population screening. ✨ 📄 mdpi.com/2072-6694/18/6… #AI #Oncology #CRC #PrecisionMedicine @mystlukes @MassiveBio @Cancers_MDPI @AmericanCancer @coloncancertask @GlobalCRC #coloncancer

@DrSukeshiArora @BallenDF @BernabeCarolina @MadisonConces @JeffreyFarma @gimedonc @DanengLi @rutikamehtaMD @smodimd @graokane @aparna1024 @ShrutiPatelMD @MPishvaian @ARosen380 @JacquelyneGMD @DrKatePedersen

#GI26 NEOSUMMIT-01, now presented 🔥 Randomized Ph II perioperative oxaliplatin-based doublet (CAPEOX or SOX) ± PD-1 inhibitor toripalimab in cT3–4N+ GC/GEJC. For context: perioperative chemotherapy alone has produced only modest gains for decades, with relapse (especially peritoneal) remaining the dominant failure pattern. NEOSUMMIT-01 delivers something we have not seen before 👇 📈 3-year EFS 74.7% vs 56.2%, HR 0.51, P=0.044 📊 3-year OS 81.3% vs 72.2%, HR 0.45, P=0.036 🚫 Metastasis/relapse nearly cut in half: 18.5% vs 38.9%, P=0.019 ⏳ mEFS not reached with perioperative chemoIO vs 38.2 months with chemo alone Benefits held up in per-protocol analyses and after excluding dMMR patients. 🔥 The dramatic reduction in peritoneal relapse is the standout. CAVEAT: China only study. Unclear if results will translate to a global population. These are fantastic results and set a high bar for perioperative chemoIO in locally advanced GC/GEJC. @OncoAlert @TheGutOncLab

#GI26 KEYNOTE-937 (phase III) 🔀 Adj HCC (PEM vs PBO) after complete radiologic response (resection/ablation) 📉 RFS: 46.7 vs 45.5 mo; (HR 1.06; P=0.72) 📉 OS: 48-mo OS 79% vs 81% 🛡️ Higher grade ≥3 AEs with pembrolizumab ➡️ Adj PEM does not improve outcomes in this setting @OncoAlert @Larvol

As highlighted @asco #gi26, the development of #KRAS inhibitors underscores not only therapeutic promise, but the critical need to understand mutation-specific biology and resistance. Trials are looking at front-line combinations, perioperative settings, maintenance strategies.

Great Keynote by Dr. Kimryn Rathmell at @asco #GI26: “Meeting Cancer Patients Where They Are: The Role of Dyad Partnerships in Oncology”

Excellent summary of two important #HCC abstracts at #GI26 by my mentor and colleague Tim Greten @ASCO @DanengLi @DaniCastilloMD

#GI26 LBA285 🔥 HORIZON-GEA-01 is presenting now. We have a new first line. Phase III, 1L HER2+ GEA Zanidatamab + chemo ± tislelizumab vs trastuzumab + chemo Key takeaways 👇 PFS significantly improved in both zanidatamab arms OS significantly improved with zanidatamab + chemo + tislelizumab Zanidatamab + chemo alone not significant at first interim Cross-trial context matters. Median OS 26.4 months here vs ~20 months in KEYNOTE-811. Zanidatamab + chemo + tislelizumab is a new 1L standard for HER2+ GEA 🚀 @OncoAlert @TheGutOncLab

We’re excited to announce our Featured Voices for the 2026 ASCO Gastrointestinal Cancers Symposium! Get their expert perspectives, find out which abstracts and sessions they’re most excited about, and join the conversation with the official meeting hashtag, #GI26.